Raid Aljumaily to Mutation
This is a "connection" page, showing publications Raid Aljumaily has written about Mutation.
Connection Strength
0.135
-
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2021 01 15; 27(2):447-459.
Score: 0.135